Back to search

France· FR:65458013

DIGOXINE NATIVELLE ADULTES 0,50 mg/2 ml, solution injectable IV

A digoxin product containing digoxine, registered in France by TEOFARMA, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC C01AA05

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedDIGOXINE NATIVELLE ADULTES 0,50 mg/2 …ATCC01AA05REGISTER NO.FR:65458013PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Digoxin is registered in 15 of 19 countries.

Countries holding a registration under ATC C01AA05 (digoxin), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 7 of them publish a price we can compare per daily dose

Digoxin · ATC C01AA05

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of digoxin costs, country by country.

Normalised to the WHO defined daily dose (0.25 mg), the median price runs from $0.11 in France to $0.20 in United States — a ×1.8 gap.

  • France: $0.11 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail

Digoxin · price per daily dose (0.25 mg)

USD · FX 28 Sept 2026

  • US United States$0.20 (acquisition cost)
  • FR France$0.11
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
DIGOXINE
Manufacturer
TEOFARMA
Country
France (FR)
ATC code
C01AA05
ATC class
Digoxin
Defined daily dose
0.25 mg, O
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930313893
    6 ampoule(s) en verre de 2 ml
    EUR 5.64

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

473 interactions on record for digoxin.

Graded by severity as the source publishes them — 17 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Digoxin · interactions on record

473 records

  • 17 severe
  • 178 moderate
  • 48 minor
  • 182 info

Most severe, free to view

  • DolasetronA04AA04severe
  • Calcium gluconateA12AA03severe
  • Calcium chlorideA12AA07severe
  • Calcium glucoheptonateA12AA10severe

48 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Digoxin in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All digoxin products

Authorised across Europe · EMA

The same active substance is authorised in 24 EEA countries. Names it is sold under:

  • Belgium · Lanoxin
  • Bulgaria · Дигоксин Софарма
  • Czechia · Digoxin Eneo, Digoxin Léčiva
  • Germany · Lanicor, Lanicor Ampullen
  • Denmark · Digoxin, Digoxin Dak
  • Estonia · Digoxin Eneo, Digoxin Grindeks
  • Spain · Digoxina Kern Pharma, Digoxina Teofarma
  • Finland · Digoxin Orion Mite, Orion
  • United Kingdom (Northern Ireland) · Digoxin Accord, Digoxin Accord-Uk
  • Greece · Digoxin Anfarm, Digoxin Juvisé
  • Hungary · Digoxin Eneo, Digoxin Richter
  • Ireland · Lanoxin, Lanoxin Pg
  • Italy · Lanoxin
  • Lithuania · Digoxin Sopharma
  • Luxembourg · Lanoxin
  • Latvia · Digoxicor, Digoxin Grindeks
  • Malta · Digoxin Bristol Laboratories, Digoxin Sopharma
  • Netherlands · Lanoxin 125, Lanoxin 250
  • Norway · Digoxin Orifarm
  • Poland · Digoxin Teva, Digoxin Wzf
  • Portugal · Lanoxin, Lanoxin Md
  • Romania · Digoxin Zentiva, Digoxină Zentiva
  • Sweden · Digoxin Evolan
  • Slovakia · Digoxin Eneo, Digoxin Léčiva

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/7ee68992-1ff1-4936-bf85-eeb6e4ee8e2f
GET /v1/drugs/7ee68992-1ff1-4936-bf85-eeb6e4ee8e2f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "65458013",
  "date_amm": "1989-07-03",
  "type_amm": "Procédure nationale",
  "numero_ue": null,
  "substance": "DIGOXINE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable",
  "voies_administration": "intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about digoxin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.